ScandiDos AB (SDOS) Fair Value & Analysis
Healthcare · SE · Market cap 49.0M SEK (≈ $5.1M) · ISIN SE0005768124
What is ScandiDos AB really worth?
Below-average quality, and trading another 439% above our fair value of kr 0.1615.
Risks
Fair value as of: Aug 29, 2026
From 1 valuation models · updated 3 days ago
Share price +4.8% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (kr 0.2040). The favourable scenario is already priced in.
- Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (kr 0.1020 to kr 0.2040) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 29, 2026.
How to read this chart
60‑month range kr 0.8000 – kr 4.15 · fair‑value band kr 0.1020 – kr 0.2040 · the kr 0.8700 price screens above the kr 0.1615 fair value. Dashed = 300-day average. As of Aug 29, 2026.
Analysis
ScandiDos AB (SDOS) currently trades at kr 0.8700, while our model-based Fair Value estimate is kr 0.1615, implying the stock looks roughly 438.8% overvalued today. The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Over the trailing twelve months, ScandiDos AB generated revenue of 56.9M SEK at a net margin of −7.4%. Revenue declined 23.9% year over year. It earns a return on equity of −9.6%. The balance sheet holds a net cash position of 4.4M SEK. Fundamentals as of Aug 29, 2026
Our scenario range runs from kr 0.1020 (bear case) to kr 0.2040 (bull case); at kr 0.8700, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −81%, SDOS screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 1 models by family
Notify me when SDOS reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 29, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 31
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
ScandiDos AB (publ), together with its subsidiaries, provides measurement phantoms and software solutions for the quality assurance and validation of dynamic and modulated treatments adopted in clinics in the United States, Europe, Asia, and internationally.
Full company description
ScandiDos AB (publ), together with its subsidiaries, provides measurement phantoms and software solutions for the quality assurance and validation of dynamic and modulated treatments adopted in clinics in the United States, Europe, Asia, and internationally. The company offers Delta4 products comprising Delta4 Phantom+, Delta4Phantom+MR, Delta4 HexaMotion, Delta4Insight, Delta4DVH Anatomy, Delta4 Machine QA, and Delta4 Statistics Module for the quality assurance in advanced radiation therapy techniques, such as VMAT, RapidArc, IMRT, and Tomotherapy. It sells its products directly to consumers and through distributors. ScandiDos AB (publ) was founded in 2001 and is headquartered in Uppsala, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
ScandiDos AB reported revenue of 54.2M SEK in FY2026 versus 57.7M SEK in FY2022, a compound −1.5%/yr. Reported net income was −3.4M SEK in FY2026.
SDOS screens 439% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 365 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 29, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $112.47 | $74.79 | −34% |
| Stryker Corporation SYK | $322.12 | $186.28 | −42% |
| Medtronic plc MDT | $89.97 | $65.57 | −27% |
| Boston Scientific Corporation BSX | $46.84 | $30.73 | −34% |
| Edwards Lifesciences Corporation EW | $90.78 | $41.02 | −55% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | −14% |
| DexCom, Inc DXCM | $90.82 | $38.95 | −57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | −14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | −39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | −2% |
Compare ScandiDos AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is ScandiDos AB (SDOS) overvalued or undervalued?
What is the fair value of SDOS?
What is the quality score of SDOS?
What is the revenue of ScandiDos AB (SDOS)?
What is the net profit margin of SDOS?
Watch ScandiDos AB in the live analysis
One click puts ScandiDos AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.